Mersana Therapeutics Presents Preclinical Data from its Innovative Dolasynthen and Immunosynthen ADC Platforms at American Association for Cancer Research 2020 Virtual Annual Meeting
June 22, 2020 09:05 ET
|
Mersana Therapeutics, Inc.
Preclinical data on XMT-1592, a NaPi2b-targeted site-specific and homogeneous Dolasynthen ADC, demonstrate excellent activity, tolerability and pharmacokineticsPreclinical data on multiple...
Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 02, 2020 17:24 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (Nasdaq:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Pricing of Public Offering of Common Stock
May 28, 2020 23:24 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present at Jefferies Virtual Global Healthcare Conference
May 28, 2020 17:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Proposed Public Offering of Common Stock
May 28, 2020 06:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
Mersana Therapeutics Reports Positive Interim Data from the Expansion Portion of the XMT-1536 Phase 1 Study
May 27, 2020 06:00 ET
|
Mersana Therapeutics, Inc.
- Achieved 35% objective response rate, including 10% complete response rate, and 80% disease control rate among twenty evaluable patients with ovarian cancer - Data continue to support a NaPi2b...
Mersana Therapeutics to Present Two Posters at the American Association for Cancer Research 2020 Virtual Annual Meeting
May 15, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics Announces Initiation of XMT-1592 Phase 1 Dose Escalation Study
May 14, 2020 16:05 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Present Interim Data from Phase 1 Expansion of XMT-1536 at the American Society of Clinical Oncology 2020 Virtual Scientific Program
May 13, 2020 17:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
Mersana Therapeutics to Report Interim Data from Phase 1 Dose Expansion of XMT-1536
May 13, 2020 08:00 ET
|
Mersana Therapeutics, Inc.
CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...